Search
forLearn
5 / 801 resultslearn octapeptide-2
learn Actsyl®
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn Ceramide A2
Research
5 / 512 resultsresearch Isoxazole 9 (ISX9), a small molecule targeting Axin, activates Wnt/β‐catenin signalling and promotes hair regrowth
Isoxazole 9 (ISX9) may help regrow hair by activating certain cell signals.
research ISX9, a small molecule targeting Axin, activates Wnt/β-catenin signaling and promotes hair regrowth
ISX9 helps regrow hair by activating a specific cell signaling pathway.
research Berberine promotes hair growth by targeting Axin2 and activating Wnt/β-catenin pathway
research Augmenting Endogenous Wnt Signaling Improves Skin Wound Healing
Boosting Wnt signaling improves skin wound healing.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
Community Join
5 / 1000+ resultscommunity Novel Formulation To Put An End To Hair Loss Once And For All.
A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.
community 48 days of Fin, Min, and Dermaroller
The user has been using finasteride for hair loss for 2-3 years, and added 5% topical minoxidil and daily 1.5mm dermarolling to their routine 50 days ago, which resulted in significant hair growth. The user recommends dermarolling along with minoxidil and finasteride for better results.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.